Bharat Biotech Vaccine: Lancet publishes study stating vaccine safety, triggers immune response

The use of Covaxin has been allowed under "clinical trial mode."

Covid19, The Lancet, Coronavirus, Vaccine, Covaxin, Bharat Biotech- True Scoop

Bharat Biotech's Covaxin- a vaccine against Covid-19 was given approval by Drugs and Controller General of India (DCGI) for restricted use in emergency situations. It has proven to be safe and triggers immune response in a small group of people between 18-55 years age, as per the study published in The Lancet medical journal.

Read More: Are you going to take Covaxin shot? Learn what consent form says

The use of Covaxin has been allowed under "clinical trial mode." As per the consent letter of the vaccine, the "COVAXINTM"  has been permitted in public interest for restricted use in emergency situations.

According to a report published in Reuters, Bharat Biotech's vaccine is being tested on separate 25, 800 person trial since November. Bharat Biotech said, 13,000 people participating in the late-stage of trial has been given the second dose.

Read More: Covaxin: Bharat Biotech explains side-effects, who shouldn't take it

It is the interim data published in the journal that included three different vaccine formulations and a placebo group among 375 adults. Two formulations termed COVAXIN have been taken for more advanced stage of testing and further efficacy trials are warranted, the report said.

 


Trending